European Pharmaceutical Review

FEBRUARY 7, 2023

In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR. Edward helps clients with compliance and safety issues, including in the development, launch and marketing of new products. of the MDR and Article 110.4

Medical 117

Medical Government Marketing Medicine 117

PM360

DECEMBER 14, 2022

In its latest venture into the healthcare arena, Amazon is reaching out directly to the consumer via its soon-to-be-launched Amazon Clinic , a virtual health service for patients to see licensed clinicians about common medical issues. billion euros into its new facility where it is planning to hire 400 and 500 new personal by 2027.

Manufacturing 52

Manufacturing Medical Healthcare Healthcare 52

Legacy MEDSearch

MAY 23, 2022

Surgeons are tethered to the surgical tower by a power cable and by a light cord that is often implicated in OR fires and patient burns. BN by 2027. The expected benefits include ease of use, improved OR efficiency, reduction in costs, and better patient outcomes. But we are at the dawn of a new era.

Food and Drug Administration 52

Food and Drug Administration Medicine Recruitment Physicians 52

Clarivate

AUGUST 27, 2024

With the global atrial fibrillation market at $6 billion today, that rate of growth would push it to $12 billion by mid-2027, if not sooner, with PFA accounting for about 70% of the market. In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients.

Marketing 52

Marketing FDA Competition Medical 52

Medico Reach

FEBRUARY 8, 2023

Grand View Research Pharmacovigilance market predictions: Source Monitoring the safety of cancer medicines is crucial, giving rise to the market with the oncology segment of 26.9% billion by 2027. The global pharmacovigilance (PV) market stood at USD 7.80 billion in 2022 and will expand at a CAGR of 10.3% from 2023 to 2030.

Pharma 52

Pharma Medicine Marketing Prospecting 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

European Pharmaceutical Review

MAY 4, 2023

Data announced at the European Lung Cancer Congress (ELCC) earlier this month revealed the long-term efficacy and safety of RYBREVANT ® (amivantamab) in patients with post-platinum EGFR Ex20ins-mutated advanced non-small cell lung cancer (NSCLC). 4 Amivantamab targets the extracellular portion of the EGFR and MET receptors.

Food and Drug Administration 98

Food and Drug Administration Safety Patients Medicine 98

Pharmaceutical Technology

JANUARY 10, 2023

Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D.

Marketing 52

Marketing Physicians Leads Sales 52

PM360

OCTOBER 24, 2022

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. Social Responsibility.

Pharma 40

Pharma Medicine Education Manufacturing 40

Pharmaceutical Technology

FEBRUARY 6, 2023

In an email , a Pliant spokesperson told Pharmaceutical Technology , “As currently approved therapies are not well tolerated, a new agent with a favorable safety profile and demonstrated efficacy would be a welcome addition to the IPF treatment armamentarium”. In the US, the annual cost for Esbriet is $113,193 and $112,357 for Ofev.

Marketing 59

Marketing Pharmaceutical FDA Prospecting 59